The University of Chicago Header Logo

Connection

Larry Goldstein to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Back to Details
This is a "connection" page, showing publications Larry Goldstein has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Larry Goldstein
Connection Strength
7.865
Hydroxymethylglutaryl-CoA Reductase Inhibitors
  1. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
    View in: PubMed
    Score: 0.695
  2. Association of Statin Use With Risk of Stroke Recurrence After Intracerebral Hemorrhage. Neurology. 2023 10 31; 101(18):e1793-e1806.
    View in: PubMed
    Score: 0.693
  3. Reader response: Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology. 2019 04 23; 92(17):821-822.
    View in: PubMed
    Score: 0.513
  4. Adverse Effects of Statins. JAMA. 2017 03 14; 317(10):1079.
    View in: PubMed
    Score: 0.443
  5. Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance. Neurology. 2016 04 26; 86(17):1570-1.
    View in: PubMed
    Score: 0.414
  6. Statin therapy should be discontinued in patients with intracerebral hemorrhage. Stroke. 2013 Jul; 44(7):2058-9.
    View in: PubMed
    Score: 0.342
  7. Letter by goldstein regarding article, "statins and intracerebral hemorrhage". Circulation. 2012 Jun 12; 125(23):e1015.
    View in: PubMed
    Score: 0.319
  8. Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol. 2011 May; 68(5):565-6.
    View in: PubMed
    Score: 0.289
  9. The quest for the "Holy Grail" of ischemic stroke cytoprotection: Statins may not be the answer. Neurology. 2009 Dec 15; 73(24):2058-9.
    View in: PubMed
    Score: 0.266
  10. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009 Nov; 40(11):3526-31.
    View in: PubMed
    Score: 0.263
  11. Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep. 2009 Jul; 11(4):296-300.
    View in: PubMed
    Score: 0.260
  12. JUPITER and the world of stroke medicine. Lancet Neurol. 2009 Feb; 8(2):129-31.
    View in: PubMed
    Score: 0.252
  13. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008 Sep; 39(9):2444-8.
    View in: PubMed
    Score: 0.243
  14. 10 questions about statins and stroke. Neurologist. 2008 Jul; 14(4):262-4.
    View in: PubMed
    Score: 0.242
  15. Statins for stroke prevention. Curr Atheroscler Rep. 2007 Oct; 9(4):305-11.
    View in: PubMed
    Score: 0.230
  16. Low LDL cholesterol, statins, and brain hemorrhage: should we worry? Neurology. 2007 Mar 06; 68(10):719-20.
    View in: PubMed
    Score: 0.221
  17. Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc Dis. 2004; 18(1):1-2.
    View in: PubMed
    Score: 0.182
  18. Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study. Neurology. 2023 03 07; 100(10):e1048-e1061.
    View in: PubMed
    Score: 0.165
  19. Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study. Neurology. 2022 Aug 15; 99(7):e711-e719.
    View in: PubMed
    Score: 0.161
  20. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 05 05; 75(17):2110-2118.
    View in: PubMed
    Score: 0.136
  21. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 02; 39(2):e38-e81.
    View in: PubMed
    Score: 0.126
  22. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke. 2017 12; 48(12):3245-3251.
    View in: PubMed
    Score: 0.116
  23. Chronic kidney disease and stroke. Adv Chronic Kidney Dis. 2014 Nov; 21(6):500-8.
    View in: PubMed
    Score: 0.094
  24. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct; 45(10):2974-82.
    View in: PubMed
    Score: 0.093
  25. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun; 8(3 Suppl):S5-16.
    View in: PubMed
    Score: 0.091
  26. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke. 2014 May; 45(5):1429-36.
    View in: PubMed
    Score: 0.090
  27. Modern medical management of acute ischemic stroke. Methodist Debakey Cardiovasc J. 2014 Apr-Jun; 10(2):99-104.
    View in: PubMed
    Score: 0.090
  28. Advances in stroke: Prevention and health services delivery 2012-2013. Stroke. 2014 Feb; 45(2):371-2.
    View in: PubMed
    Score: 0.089
  29. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct; 68(10):1245-51.
    View in: PubMed
    Score: 0.074
  30. Advances in prevention and health services delivery 2009. Stroke. 2010 Feb; 41(2):e71-3.
    View in: PubMed
    Score: 0.067
  31. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008 Dec; 39(12):3297-302.
    View in: PubMed
    Score: 0.062
  32. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun; 204(2):515-20.
    View in: PubMed
    Score: 0.061
  33. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009 Feb 24; 72(8):688-94.
    View in: PubMed
    Score: 0.061
  34. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May; 39(5):1647-52.
    View in: PubMed
    Score: 0.059
  35. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol. 2007 Mar 27; 99(6C):1E-35E.
    View in: PubMed
    Score: 0.055
  36. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 08 10; 355(6):549-59.
    View in: PubMed
    Score: 0.053
  37. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun; 37(6):1427-31.
    View in: PubMed
    Score: 0.052
  38. Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology. 2004 Mar 23; 62(6):968-70.
    View in: PubMed
    Score: 0.045
  39. Prevention and health services delivery. Stroke. 2004 Feb; 35(2):401-3.
    View in: PubMed
    Score: 0.045
  40. Prevention and health services delivery. Stroke. 2003 Feb; 34(2):367-9.
    View in: PubMed
    Score: 0.042
  41. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003; 16(4):389-95.
    View in: PubMed
    Score: 0.041
  42. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 12; 48(12):3223-3231.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.